Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00862056 · ClinicalTrials.gov registry record

Detection of Subclinical Atherosclerosis in Asymptomatic Individuals

A clinical trial, sponsored by Piedmont Healthcare.

Completed
Registry status
73
Enrollment target

NCT00862056: Completed study, sponsored by Piedmont Healthcare.

NCT00862056 is a clinical trial that has completed, run by Piedmont Healthcare. The registered enrollment target is 73 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00862056 has completed, sponsored by Piedmont Healthcare.

COMPLETED
Registry status
73 participants
Enrollment target

Study Summary

This study will evaluate the use of cardiac CT in identifying atherosclerosis plaque in patients who have not been diagnosed with atherosclerosis and who have no symptoms of the disease but who are at risk of developing atherosclerosis based on traditional risk factors such as diabetes or a family history of coronary artery disease.

Interventions

  • PROCEDURE Cardiac CT

Trial Details

FieldValue
Enrollment Target 73 participants
Start Date 2009-01
Est. Completion 2013-07
Piedmont Healthcare

13 total trials

What the finished NCT00862056 record still lists

NCT00862056 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 73 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which Cardiac CT is the first listed.

NCT00862056 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00862056 about?

NCT00862056 is a clinical study titled "Detection of Subclinical Atherosclerosis in Asymptomatic Individuals". This study will evaluate the use of cardiac CT in identifying atherosclerosis plaque in patients who have not been diagnosed with atherosclerosis and who have no symptoms of the disease but who are at risk of developing atherosclerosis based on traditional risk factors such as diabetes or a family h...

What is the current status of trial NCT00862056?

This trial is currently completed. The enrollment target is 73 participants. The study started on 2009-01. Estimated completion is 2013-07.

What interventions are being tested in trial NCT00862056?

The interventions under investigation include: Cardiac CT (PROCEDURE).

Who is sponsoring clinical trial NCT00862056?

This trial is sponsored by Piedmont Healthcare, which has 13 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03661307 · 73 participants · Phase 1

    Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

  • NCT05386108 · 73 participants · Phase 1

    Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

  • NCT05961592 · 73 participants · Phase 1

    R-2487 in Patients With Rheumatoid Arthritis

  • NCT06150664 · 73 participants · Phase 1

    A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00862056, the US trial registry maintained by the National Library of Medicine. NCT00862056 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.